BG
TNGX icon

Bellevue Group’s Tango Therapeutics TNGX Stock Holding History

Bellevue Group’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7M Sell
694,182
-1,705,818
-71% -$42.2M 0.46% 50
2026
Q1 		$50.2M Sell
2,400,000
-1,527,670
-39% -$21.3M 1.19% 26
2025
Q4 		$34.8M Buy
+3,927,670
New +$33.8M 0.66% 37

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Bellevue Group's TNGX Position: Q2 2026 in Review

Bellevue Group reduced its Tango Therapeutics (TNGX) stake by 71% in Q2 2026, selling an estimated $42.2M and leaving 694,182 shares worth $21.7M. The position accounts for 0.46% of the portfolio, ranked #50.

Bellevue Group first reported a position in TNGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $50.2M in Q1 2026. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Bellevue Group held 694,182 shares of Tango Therapeutics worth $21.7M as of Q2 2026.
  • Bellevue Group sold 1,705,818 Tango Therapeutics shares in Q2 2026, an estimated $42.2M.
  • Tango Therapeutics made up 0.46% of Bellevue Group's portfolio in Q2 2026, its #50 holding.
  • Bellevue Group first reported a position in Tango Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Bellevue Group's Tango Therapeutics position peaked at $50.2M in Q1 2026.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.